#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurodermatitis Thromboangiitis obliterans Glomerulonephritis membranous Acute on chronic liver failure Angiosarcoma recurrent Undifferentiated sarcoma Dementia Craniopharyngioma Kawasaki's disease Glycogen storage disease type I Optic glioma Mucopolysaccharidosis II Germ cell cancer Transplant rejection Small cell lung cancer limited stage More trials…

    Learn about Rare Diseases

    Atypical teratoid/rhabdoid tumour of CNS – Basic Information Marfan’s syndrome – Trials in Disease Glycogen storage disease type V – Treatment Rhabdomyosarcoma – Basic Information Stevens-Johnson syndrome – Basic Information Mast cell activation syndrome – Basic Information Behcet’s syndrome – Diagnostics Rhabdomyosarcoma recurrent – Diagnostics Rhabdomyosarcoma – Trials in Disease Nephrotic syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dexibuprofen Cefaclor Corylus Avellana L. XENON (133XE) REGN7999 Pegipanermin Meropenem Zoledronic Acid Monohydrate Tirbanibulin Selpercatinib Dog Epithelia SODIUM BENZOATE Gadoteridol Nefopam Hydrochloride Lifileucel Enzalutamide Valganciclovir Gad20-209-Fsp-A2 Leucine Carbasalate Calcium More therapies…

    Learn about Your Condition

    Albright's disease Genitourinary tract neoplasm Cartilage injury Deafness Myotonia Langerhans' cell histiocytosis Adenomatous polyposis coli Vulval cancer recurrent Lipid metabolism disorder Hypertrophic cardiomyopathy Acquired ATTR amyloidosis Rhabdoid tumour of the kidney Pancreatic carcinoma recurrent Juvenile psoriatic arthritis Prinzmetal angina More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Specjalistyczny gabinet dermatologiczny Aplikacyjno-Badawczy…

Specjalistyczny gabinet dermatologiczny Aplikacyjno-Badawczy M. Brzewski, P. Brzewski S.C.

Ul. Zbożowa 2/25, Cracow, 30-002, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata

    Recruiting

    2 1
    Investigated Diseases:
    • Alopecia areata
    Bulgaria Germany Poland Romania Spain

  • Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

    Recruiting

    3 1 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Abrocitinib
    Germany Hungary Poland Spain

  • Effectiveness and Safety of Abrocitinib in Children 6 to Under 12 Years with Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Abrocitinib
    Germany Hungary Poland Spain

  • Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Previously Used Biologic Treatments

    Recruiting

    3 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Jnj-77242113
    Bulgaria Czechia Denmark Germany Hungary Italy +3

  • Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Litifilimab
    Belgium Bulgaria France Germany Hungary Italy +5

  • A study to evaluate the long-term safety and effectiveness of afimkibart in patients with atopic dermatitis who took part in previous afimkibart studies

    Recruiting

    2 1
    Investigated Diseases:
    • Dermatitis atopic
    Investigated Drugs:
    • Ro7790121
    France Germany Italy Poland Spain

  • A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Lichen sclerosus
    France Germany Italy Poland Spain

  • Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Alopecia areata
    Czechia France Italy Poland Spain

  • Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    • Jnj-77242113
    Germany Hungary Italy Poland Romania Spain

  • Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    • Jnj-77242113
    France Germany Hungary Italy Poland Spain
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!